ADA: Semaglutide Similarly Effective in Men, Women With Obesity-Linked Heart Failure
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 26, 2024 -- For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide reduces body weight to a greater extent in women but yields similar improvements in heart failure-related symptoms in men and women, according to a study published online June 23 in the Journal of the American College of Cardiology to coincide with the annual meeting of the American Diabetes Association, held from June 21 to 24 in Orlando, Florida.
Subodh Verma, M.D., Ph.D., from the University of Toronto, and colleagues examined the baseline characteristics and treatment effect of semaglutide by sex across the STEP-HFpEF program. Patients with heart failure, left ventricular ejection fraction ≥45 percent, body mass index ≥30 kg/m2, and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) <90 points were randomly assigned to receive once-weekly semaglutide 2.4 mg or matched placebo for 52 weeks. Data were included for 1,145 patients (49.7 percent female).
The researchers found that regardless of sex, semaglutide improved KCCQ-CSS (mean difference in women and men, +7.6 and +7.5, respectively), but reduced body weight more in women than men (mean difference, −9.6 and −7.2 percent, respectively). In both sexes, semaglutide improved six-minute walk distance (6MWD) and the hierarchical composite end point comprising all-cause death, heart failure events, changes in KCCQ-CSS, and 6MWD. Compared with placebo, there were fewer serious adverse events with semaglutide.
"Despite greater reductions in weight in females than males, semaglutide produced similar, clinically meaningful improvements in heart failure-related symptoms, physical limitations, and exercise function, along with reductions in inflammation and natriuretic peptides, regardless of sex," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Heart Failure Tied to Worsening of Neuropsychological Symptoms
TUESDAY, April 22, 2025 -- Patients with heart failure experience worsening neuropsychological outcomes over six months, according to a study published online April 8...
Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk
MONDAY, April 21, 2025 -- Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.